NTAGI to review trial data on SII's qHPV vaccine against cervical cancer

Serum Institute of India Director for Government and Regulatory Affairs Prakash Kumar Singh applied to the Drugs Controller General of India (DCGI) seeking market authorisation for the vaccine after the phase 2/3 clinical trial was completed with the support of the Department of Biotechnology to ensure its early availability in the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cXib4Gp
via IFTTT